Cornovus Pharmaceuticals Overview

  • Founded
  • 2011
  • Status
  • Out of Business
  • Latest Deal Type
  • Out of Business

Cornovus Pharmaceuticals General Information


Developer of heart attack drug designed to treat cardiac hypertrophy and heart failure. The company's heart failure drug increases myocardial cyclic guanosine-monophosphate which may play a role in cardia function and reperfusion, enabling heart attack victims to delay the onset of heart failure after a heart attack or injury.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Other Healthcare Technology Systems
Other Industries
Other Pharmaceuticals and Biotechnology
Primary Office
  • 400 Farmington Avenue
  • MC 6409
  • Farmington, CT 06032
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Cornovus Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Out of Business 01-Nov-2017 000 Completed Out of Business
3. Early Stage VC (Series A) 23-May-2017 00.00 000 Completed Product Development
2. Early Stage VC (Series A) 28-Feb-2014 $1.59M $1.7M Completed Startup
1. Seed Round 28-Feb-2013 $110K $110K Completed Startup
To view Cornovus Pharmaceuticals’s complete valuation and funding history, request access »

Cornovus Pharmaceuticals Cap Table

Stock # of Shares
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 00,000 00.000000 00 000.00 000.00 00 000.00 00.000
To view Cornovus Pharmaceuticals’s complete cap table history, request access »

Cornovus Pharmaceuticals Executive Team (2)

Name Title Board Seat Contact Info
Mark Van Allen Acting Chief Operating Officer
You’re viewing 1 of 2 executive team members. Get the full list »